Publications by authors named "Ellen Shrader"

Claim this Profile
A
A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.
Andrew S Poklepovic, Sarah W Gordon, Sejal Kothadia, William P McGuire, Leroy R Thacker, Ellen Shrader

Anticancer Drugs· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma.
Andrew S Poklepovic, Palak Shah, Mary Beth Tombes, Ellen Shrader, Dipankar Bandyopadhyay

medRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Danielle Shafer, Amanda B Kagan, Michelle A Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader

Cancer Chemother Pharmacol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep Dave, Prithviraj Bose, Ellen Shrader

Leuk Lymphoma· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma.
Danielle Shafer, Mary Beth Tombes, Ellen Shrader, Alison Ryan, Dipankar Bandyopadhyay

Neurooncol Adv· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Sarah W Gordon, William P McGuire, Danielle A Shafer, Richard K Sterling, Hannah M Lee, E Ellen Shrader

Am J Clin Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Victor Yazbeck, Danielle Shafer, Edward B Perkins, Domenico Coppola, Lubomir Sokol, Ellen Shrader

Clin Lymphoma Myeloma Leuk· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
Beata Holkova, Victor Yazbeck, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Ellen Shrader

Leuk Lymphoma· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Victor Y Yazbeck, Paul M Barr, Ellen Shrader

Leuk Lymphoma· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Andrew Poklepovic, Sarah Gordon, Danielle A Shafer, John D Roberts, Prithviraj Bose, Ellen Shrader

Oncotarget· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z Badros, Ellen Shrader

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Beata Holkova, Maciej Kmieciak, E Brent Perkins, Prithviraj Bose, Rachid C Baz, Ellen Shrader

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Beata Holkova, Jeffrey G Supko, Matthew M Ames, Joel M Reid, Geoffrey I Shapiro, Ellen Shrader

Clin Cancer Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis